The second tier of Instant Molecular Testing Service segmentation is organized by technology type, each subtype delivering distinct analytical performance and workflow characteristics. PCR‑based assays remain the benchmark, offering quantitative amplification with cycle‑threshold readouts; their robustness and established supply chains support roughly 50 % of device shipments. Isothermal amplification methods, such as LAMP and RPA, eliminate thermal cycling, reducing instrument complexity and enabling true point‑of‑care deployment, accounting for about 25 % of market volume. CRISPR‑based detection leverages programmable nucleases for sequence‑specific cleavage coupled with fluorescent reporters, a rapidly emerging subtype that currently captures 15 % of sales despite higher reagent costs. Hybrid‑capture platforms combine target enrichment with rapid sequencing, suited for multiplex panels and pathogen surveillance, contributing the remaining 10 % of revenue. This technology‑focused taxonomy illustrates how each type’s cost structure, assay time, and scalability shape its share of the overall Instant Molecular Testing Service market. Adoption trends indicate that cost‑per‑test reductions and integration with digital health platforms are accelerating the shift toward isothermal and CRISPR‑based solutions, especially in low‑resource environments.